Adi Mohanty
Chief Executive Officer at BIORA THERAPEUTICS, INC.
Net worth: 97 752 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Brian Culley | M | 53 | 6 years | |
| Eric d'Esparbes | M | 56 | 5 years | |
| Jeffrey Alter | M | 61 | 5 years | |
| Robert W. Peabody | M | 69 |
Cell Cure Neurosciences Ltd.
 Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 9 years |
| David Schlachet | M | 78 |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 5 years |
| Andy Arno | M | 64 | 9 years | |
| Brian Kotzin | M | 74 | 5 years | |
| Jill Howe | F | 48 | 3 years | |
| Lynne Powell | F | 57 | 5 years | |
| Andrew Last | M | 64 | 9 years | |
| Jeffrey Allen Ferrell | M | 49 | 10 years | |
| Clarke Neumann | M | 60 | 10 years | |
| Michael Rhode | M | - | - | |
| Allison Luo | M | 50 | 7 years | |
| Robyn Hatton | F | - | 11 years | |
| Francine Del Ricci | F | - |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | - |
| Michael D. West | M | - |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 22 years |
| Gary Hogge | M | 56 | 6 years | |
| Frank Lanza | M | 62 | 8 years | |
| Leslie Waltke | F | - | 12 years | |
| Paul W. Shabram | M | - | 2 years | |
| Raf Hofstein | M | 74 |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | - |
| Benjamin Reubinoff | M | - |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 18 years |
| Rami Skaliter | M | 66 |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 7 years |
| Sharat Singh | M | - | - | |
| Ariella Kelman | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Russell Skibsted | M | 65 | 4 years | |
| Cavan Redmond | M | 63 | 7 years | |
| Graham Hetherington | M | 65 | 6 years | |
| Ronald Andrews | M | 64 | 4 years | |
| Steve Cartt | M | 61 | 5 years | |
| Don Bailey | M | 78 | 3 years | |
| Michael West | M | 71 | 16 years | |
| William Annett | M | 70 | 4 years | |
| Ryan D. Chavez | M | 48 | 3 years | |
| Stephana Patton | M | 54 | 2 years | |
| Pedro Lichtinger | M | 70 | 2 years | |
| Michael Mulroy | M | 58 | 2 years | |
| Susan Kilsby | F | 65 | 8 years | |
| Angus Russell | M | 68 | 14 years | |
| James Bowling | M | 56 | 10 years | |
| Albert Parker | M | 58 | 2 years | |
| William Haack | M | - | 2 years | |
| Dominic Blakemore | M | 54 | 4 years | |
| Surbhi Sarna | F | 38 | 2 years | |
| Melinda Griffith | F | 69 | - | |
| Tony Kalajian | M | 54 | 4 years | |
| Doug Treco Treco | M | 66 |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 17 years |
| William Burns | M | 76 | 8 years | |
| David R. Ginsburg | M | 71 | 8 years | |
| Steven Gillis | M | 71 | 7 years | |
| Ian Karp | M | - | 5 years | |
| Howard I. Scher | M | 72 | 3 years | |
| Flemming Ørnskov | M | 66 | 6 years | |
| William Ciambrone | M | 60 |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | 9 years |
| Padma Sundar | F | - | 3 years | |
| David Stout | M | 69 | 6 years | |
| Mitchell Levine | M | - | - | |
| Ludovic Robin | M | - | 8 years | |
| Anne Minto | F | 70 | 8 years | |
| Tamara Joseph | F | 61 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 1 years |
| Kim Dickinson | M | - | 2 years | |
| Damon Silvestry | M | 56 | 2 years | |
| Kristine C. Mechem | M | - | 4 years | |
| Paul Streck | M | 60 | 2 years | |
| Joanne Cordeiro | F | 66 | 8 years | |
| Roger Adsett | M | 55 | 11 years | |
| David Jin | M | 56 | 8 years | |
| Daniel Dolan | M | 47 | 12 years | |
| Debra Silberg | M | - | - | |
| Iain Ward | M | - | 8 years | |
| Perry Sternberg | M | 55 | 6 years | |
| Theresa Heggie | F | 63 | 3 years | |
| Jill Quigley | F | 49 | 4 years | |
| David Colpman | M | 62 | 15 years | |
| Joff Masukawa | M | - | - | |
| David MacKney | M | 56 | 3 years | |
| Jeffrey Leiden | M | 68 | 6 years | |
| David Mott | M | 58 | 2 years | |
| Jonathan Leff | M | 55 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 5 years |
| Kevin Rakin | M | 63 | 1 years | |
| Barry James Price | M | 80 | 14 years | |
| Patrick J. Langlois | M | 78 | 6 years | |
| Barbara H. Deptula | F | 69 | 8 years | |
| Kathleen Anne Nealon | F | 70 | 4 years | |
| Michael Rosenblatt | M | 76 | 1 years | |
| Mark Enyedy | M | 60 | 3 years | |
| Michael G. Vicari | M | - | 1 years | |
| Brooke Clarke | F | - | 5 years | |
| Deanna M. Petersen | F | 62 | 6 years | |
| John Mauldin | M | - | - | |
| Simon Gibbins | M | 58 | 9 years | |
| Charlotte Sibley | F | 77 | 5 years | |
| Mario David Saltarelli | M | 63 | 2 years | |
| Ann Powell | F | 58 | 4 years | |
| Obed M. Cepeda | M | - |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 1 years |
| Raymond Pratt | M | 73 | 7 years | |
| Georgia Erbez | F | 57 | 1 years | |
| Arthur Tzianabos | M | 60 | 8 years | |
| Miguel Coego Rios | M | - | 8 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 51 | 51.00% |
| Ireland | 45 | 45.00% |
| Israel | 7 | 7.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Adi Mohanty
- Personal Network
